Comments on the Women's Health Initiative (WHI) and the Million Women Study (MWS) which question the usefulness of hormone substitution during menopause;Que penser des résultats de la Women's Health Initiative (WHI) et de la Million Women Study (MWS) qui remettent en question l'intérê t du traitement hormonal de la ménopause?

Journal de Gynecologie Obstetrique et Biologie de la Reproduction

Volumn 32, Issue 6, 2003, Pages 500-502

  Lopes, P ^a  

^a NANTES UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; PLACEBO; PROGESTERONE;

BODY MASS; CARCINOGENESIS; CAUCASIAN; CLINICAL STUDY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; EDITORIAL; EPIDEMIOLOGICAL DATA; FEMALE; FOOD AND DRUG ADMINISTRATION; HORMONE SUBSTITUTION; HUMAN; INTERNET; MEDICAL LITERATURE; MENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PROSPECTIVE STUDY; PUBLICATION; RANDOMIZED CONTROLLED TRIAL;

BREAST NEOPLASMS; CARDIOVASCULAR DISEASES; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; PHYSICIAN'S ROLE; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS;

EID: 0142215235     PISSN: 03682315     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (9)

1. Collaborative group on hormonal factors in breast cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52705 women with breast cancer and 108411 women without breast cancer. Lancet 1997; 350: 1047-59.
2. WHI. Writing group for the women's health initiative investigators. Risks and benefits of estrogen plus progestin in healthy post menopausal women. JAMA 2002; 288: 321-33.
3. Chlebowski RT, Hendrix SL, Langer RD, Stefanick ML, gass M, Lane D, Rodabough RJ, Gilligan MA, Cyr MC, Thomson CA, Khandekar J, Petrovitch H, Mctiernan A for the WHI investigators. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women. The women's health initiative randomized trial. JAMA 2003; 289: 3243-53.
4. Rapp SR, Espeland MA, Shumaker SA for the WHIMS investigators Effect of Estrogen plus progestin on global cognitive function in postmenopausal women. JAMA 2003; 289: 2663-72.
5. Shumaker SA, Legault C, Rapp SR, Thal L, Wallace RB, Ockene JK, Hendrix SL, Jones III BN, Assaf AR, Jackson RD, Kotchen JM, Wassertheil-Smoller S, Wactawski-Wende J for the WHIMS investigators. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women. JAMA 2003; 289: 2651-62.
6. Hays J, Ockene JK, Brunner RL, Kotchen JM, Manson JE, Patterson RE, Aragaki AK, Shumaker SA, Brzyski RG, Lacroix AZ, Granek IA, Valanis BG, for the Women's Health Initiative. Effects of Estrogen plus progestin on health-related quality of life. New Engl J Med 2003; 348: 1839-54.
7. Million women study collaborators. Breast cancer and hormone replacement therapyin the million women study. Lancet 2003; 362: 419-27.
8. Lagro-Janssen T, Rosser WW, Van Weel C. Breast cancer and hormone replacement therapy: up to general practice to pick up the pieces. Lancet 2003; 362: 414-5.
9. Scarabin PY, Oger E, Plu-Bureau G, on behalf of the estrogen and thromboembolism risk (ESTHER) study group. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet 2003; 362: 428-32.